Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
NDM Pharma provides POC for NMD670
In Science Translational Medicine the team headed by Thomas Holm Pedersen from NDM Pharma A/S report that they have conducted animal studies and a...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...